Genetic study of schizophrenia: new targets for therapy

References

• World Health Report www.who.int/ whR2001/2001/ (2001).
   Google Scholar
• Gottesman II, Bertelsen A. Confirming unexpressed genotypes for schizophrenia. Risks in the offspring of Fischer's Danish identical and fraternal discordant twins. Arch. Gen. Bychiatry46, 867–872 (1989).
   Google Scholar
• Kendler KS. Overview: a current perspective on twin studies of schizophrenia. Am.j Bychiatry 140,1413–1425 (1983).
   PubMed Web of Science ®Google Scholar
• Karayiorgou M, Gogos JA. Dissecting the genetic complexity of schizophrenia. Mal Bychiatry2, 211–223 (1997).
   PubMedGoogle Scholar
• Tsuang MT, Stone WS, Faraone SV. Schizophrenia: a review of genetic studies. Harv. Rev. Psychiatry7, 185–207 (1999).
   Google Scholar
• Riley BP, McGuffin P Linkage and associated studies of schizophrenia. Am. J. Merl Genet 97,23–44 (2000).
   PubMed Web of Science ®Google Scholar
• Baron M. Genetics of schizophrenia and the new millennium: progress and pitfalls.Am. Hum. Genet. 68,299–312 (2001).
   PubMed Web of Science ®Google Scholar
• Bray NJ, Owen MJ. Searching for schizophrenia genes. Trends Mal Merl 7, 169–174 (2001).
   PubMedGoogle Scholar
• Dubertret C, Gorwood P, Ades J eta]. Meta-analysis of DRD3 gene and schizophrenia: ethnic heterogeneity and significant association in Caucasians. Am. J. Med. Genet. 81,318-322 (1998).
   Google Scholar
• Williams J, McGuffin P, Nothen M eta]. Meta-analysis of association between the 5-HT2A receptor T102C polymorphism and schizophrenia EMASS Collaborative Group. European Multicentre Association Study of Schizophrenia. Lancet349, 1221 (1997).
   Google Scholar
• Shifman S, Bronstein M, Sternfeld M eta]. A Highly significant association between a COMT haplotype and schizophrenia. Am. .1. Hum. Genet 71,1296–1302 (2002).
   Google Scholar
• Fenton WS, Hibbeln J, Knable M. Essential fatty acids, lipid membrane abnormalities and the diagnosis and treatment of schizophrenia. Biol. Rychiatry 47, 8–21 (2000).
   Google Scholar
• •Good review of phospholipids and schizophrenia.
   Google Scholar
• Horrobin DE The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia. Schizophr Res. 30,193–208 (1998).
   Google Scholar
• Gattaz WF, Kollisch M, Thuren T eta]. Increased plasma phospholipase-A2 activity in schizophrenic patients: reduction after neuroleptic therapy. Biol. Rychiatry22, 421–426 (1987).
   Google Scholar
• Noponen M, Sanfilipo M, Samanich K et al Elevated PLA2 activity in schizophrenics and other psychiatric patients. Biol. Psychiatry 34,641–649 (1993).
   Google Scholar
• Ross BM, Hudson C, Erlich J eta]. Increased phospholipid breakdown in schizophrenia. Evidence for the involvement of a calcium-independent phospholipase A2. Arch. Gem Bychiatry54, 487–494 (1997).
   Google Scholar
• Gattaz WF, Schmitt A, Maras A. Increased platelet phospholipase A2 activity in schizophrenia. Schizophr Res. 16,1-6 (1995).
   Google Scholar
• Pettegrew JW, Keshavan MS, Panchalingam K etal Alterations in brain high-energy phosphate and membrane phospholipid metabolism in first-episode, drug-naive schizophrenics. A pilot study of the dorsal prefrontal cortex by in vivo phosphorus 31 nuclear magnetic resonance spectroscopy. Arch. Gen. PTchiatry48, 563–568 (1991).
   Google Scholar
• Stanley JA, Williamson PC, Drost DJ etal An in vivo study of the prefrontal cortex of schizophrenic patients at different stages of illness via phosphorus magnetic resonance spectroscopy. Arch. Gem Psychiatry 52, 399–406 (1995).
   PubMed Web of Science ®Google Scholar
• Deicken RF, Calabrese G, Merrin EL etal 31phosphorus magnetic resonance spectroscopy of the frontal and parietal lobes in chronic schizophrenia Biol. PTchiatry36, 503–510 (1994).
   PubMedGoogle Scholar
• Shioiri T, Kato T, Inubushi T et al Correlations of phosphomonoesters measured by phosphorus-31 magnetic resonance spectroscopy in the frontal lobes and negative symptoms in schizophrenia. Psychiatry Res. 55,223–235 (1994).
   PubMedGoogle Scholar
• Deicken RF, Merrin EL, Floyd TC et al Correlation between left frontal phospholipids and Wisconsin Card Sort Test performance in schizophrenia. Schizophr Res. 14,177–181 (1995).
   PubMed Web of Science ®Google Scholar
• Hudson CJ, Kennedy JL, Gotowiec A etal Genetic variant near cytosolic phospholipase A2 associated with schizophrenia. Schizophr Res. 21,111–116 (1996).
   PubMedGoogle Scholar
• Price SA, Fox H, St Clair D etal Lack of association between schizophrenia and a polymorphism close to the cytosolic phospholipase A2 gene. Rychiatr Genet. 7, 111–114 (1997).
   PubMedGoogle Scholar
• Peet M, Ramchand CN, Lee J etal Association of the BanI dimorphic site at the human cytosolic phospholipase A2 gene with schizophrenia. PTchiatr Genet. 8, 191–192 (1998).
   PubMedGoogle Scholar
• Takehisa Y, Ujike H, Takaki M etal. Association between schizophrenia and a polymorphism of cytosolic phosphatase A2 gene. Am. J. Med. Genet. 96,534 (2000).
   Google Scholar
• Emsley R, Myburgh C, Oosthuizen P et al Randomized, placebo-controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia. Am. J. PTchiatry159,1596–1598 (2002).
   PubMed Web of Science ®Google Scholar
• Joy CB, Mumby-Croft R, Joy LA. Polyunsaturated fatty acid (fish or evening primrose oil) for schizophrenia. Cochrane Database Syst. Rev 2, (2000)
   Google Scholar
• Wittekindt O, Jauch A, Burgert E etal The human small conductance calcium-regulated potassium channel gene (hSKCa3) contains two CAG repeats in exon 1, is on chromosome 1q21.3 and shows a possible association with schizophrenia. Neurogenetics 1,259–265 (1998).
   Google Scholar
• Brzustowicz LM, Hodgkinson IKA, Chow EW etal Location of a major susceptibility locus for familial schizophrenia on chromosome 1q21-q22. Science 288,678–682 (2000).
   PubMed Web of Science ®Google Scholar
• Asherson P, Walsh C, Williams J etal Imprinting and anticipation. Are they relevant to genetic studies of schizophrenia? Br. J. Psychiatry 164,619–624 (1994).
   Google Scholar
• Bassett AS, Honer WG. Evidence for anticipation in schizophrenia. Am. J. Hum. Genet. 54,864–870 (1994).
   PubMed Web of Science ®Google Scholar
• Thibaut F, Martinez M, Petit M etal Further evidence for anticipation in schizophrenia. Psychiatry Res. 59,25–33 (1995).
   PubMedGoogle Scholar
• O'Donovan MC, Guy C, Craddock N etal Expanded CAG repeats in schizophrenia and bipolar disorder. Nat. Genet. 10,380–381 (1995).
   PubMed Web of Science ®Google Scholar
• •First report indirectly showing expansion of CAG repeats in genomes of schizophrenics.
   Google Scholar
• Chandy KG, Fantino E, Wittekindt O etal Isolation of a novel potassium channel gene hSKCa3 containing a polymorphic CAG repeat: a candidate for schizophrenia and bipolar disorder? Mal Bychiatry 3,32–37 (1998).
   PubMed Web of Science ®Google Scholar
• Bowen T, Guy CA, Craddock N etal Further support for an association between a polymorphic CAG repeat in the hKCa3 gene and schizophrenia. Mal Bychiatry 3, 266–269 (1998).
   PubMedGoogle Scholar
• Dror V, Shamir E, Ghanshani S etal hKCa3/KCNN3 potassium channel gene: association of longer CAG repeats with schizophrenia in Israeli Ashkenazi Jews, expression in human tissues and localization to chromosome 1q21. Mol Psychiatry 4, 254–260 (1999).
   PubMedGoogle Scholar
• Ujike H, Yamamoto A, Tanaka Y etal Association study of CAG repeats in the KCNN3 gene in Japanese patients with schizophrenia, schizoaffective disorder and bipolar disorder. Bychiatry Res. 101,203–207 (2001).
   Google Scholar
• Li T, Hu X, Chandy KG etal Transmission disequilibrium analysis of a triplet repeat within the hKCa3 gene using family trios with schizophrenia. Biochem. Biophys. Res. Commun. 251,662-665 (1998).
   Google Scholar
• Wittekindt O, Schwab SG, Burgert E etal Association between hSKCa3 and schizophrenia not confirmed by transmission disequilibrium test in 193 offspring/parents trios. Ma/ Psychiatry 4, 267–270 (1999).
   PubMedGoogle Scholar
• Antonarakis SE, Blouin JL, Lasseter VK etal Lack of linkage or association between schizophrenia and the polymorphic trinucleotide repeat within the KCNN3 gene on chromosome 1q21. Am. J. Med. Genet. 88,348-351 (1999).
   Google Scholar
• Bonnet-Brilhault F, Laurent C, Campion D etal No evidence for involvement of KCNN3 (hSKC4 potassium channel gene in familial and isolated cases of schizophrenia. Eur J. Hum. Genet. 7,247-250 (1999).
   Google Scholar
• Guy CA, Bowen T, Williams N etal No association between a polymorphic CAG repeat in the human potassium channel gene hKCa3 and bipolar disorder. Am. J. Med Genet. 88,57-60 (1999).
   Google Scholar
• McInnis MG, Breschel TS, Margolis RL etal Family-based association analysis of the hSKCa3potassium channel gene in bipolar disorder. Mal Psychiatry 4,217–219 (1999).
   PubMed Web of Science ®Google Scholar
• Hawi Z, Mynett-Johnson L, Murphy V etal. No evidence to support the association of the potassium channel gene hSKCa3 CAG repeat with schizophrenia or bipolar disorder in the Irish population. Mol. Psychiatry 4,488–491 (1999).
   Google Scholar
• Cardno AG, Bowen T, Guy CA etal. CAG repeat length in the hKCa3 gene and symptom dimensions in schizophrenia. Biol. Psychiatry 45,1592–1596 (1999).
   Google Scholar
• Ritsner M, Modai I, Ziv H etal An association of CAG repeats at the KCNN3 locus with symptom dimensions of schizophrenia. Biol. Bychiatry5 I, 788–794 (2002).
   Google Scholar
• Su TE Evidence for sigma opioid receptor: binding of [3H1SKF-10047 to etorphine- inaccessible sites in guinea-pig brain. J. Pharmacol Exp. Ther 223,284–290 (1982).
   Google Scholar
• Ujike H, Akiyama K, Kuroda S. [3H1YM-09151-2 (nemonapride), a potent radioligand for both sigma 1 and sigma 2 receptor subtypes. Neuromport 7,1057–1061 (1996).
   Google Scholar
• Davidson J, Miller R, Wingfield M et al The first clinical study of BW-234U in schizophrenia. PTchopharmacol Bull. 18, 173–176 (1982).
   PubMedGoogle Scholar
• Gewirtz GR, Gorman JM, Volavka J et al BMY 14802, a sigma receptor ligand for the treatment of schizophrenia. Neuropsychopharmacology10, 37–40 (1994).
   PubMed Web of Science ®Google Scholar
• Muller MJ, Grunder G, Wetzel H eta]. Antipsychotic effects and tolerability of the sigma ligand EMD 57445 (panamesine) and its metabolites in acute schizophrenia: an open clinical trial. Psychiatry Res. 89, 275–280 (1999).
   Google Scholar
• Ujike H, Kanzaki A, Okumura K eta]. Sigma (sigma) antagonist BMY 14802 prevents methamphetamine-induced sensitization. Life Sci. 50, PL-129—PL-134 (1992).
   Google Scholar
• Ujike H, Kuroda S, Otsuki S. Sigma receptor antagonists block the development of sensitization to cocaine. Eur. Pharmacol 296,123–128 (1996).
   Google Scholar
• Okuyama S, Ogawa S, Nakazato A eta]. Effect of NE-100, a novel sigma receptor ligand, on phencyclidine-induced delayed cognitive dysfunction in rats. Neurosci. Lett. 189,60-62 (1995).
   Google Scholar
• Reynolds GP, Brown JE, Middlemiss DN. [3H]ditolylguanidine binding to human brain sigma sites is diminished after haloperidol treatment. Eur. j Pharmacol 194,235–236 (1991).
   Google Scholar
• Weissman AD, Casanova ME, Kleinman JE et al Selective loss of cerebral cortical sigma but not PCP binding sites in schizophrenia. Biol. PTchtry29, 41–54 (1991).
   PubMed Web of Science ®Google Scholar
• Kekuda R, Prasad PD, Fei YJ etal Cloning and functional expression of the human Type 1 sigma receptor (hSigmaR1). Biochem. Biophys. Res. Commun. 229,553-558 (1996).
   Google Scholar
• Prasad PD, Li HVV, Fei YJ eta]. Exon— intron structure, analysis of promoter region and chromosomal localization of the human Type 1 sigma receptor gene. Neurochem. 70,443-451 (1998).
   Google Scholar
• Ishiguro H, Ohtsuki T, Tom M et al Association between polymorphisms in the Type 1 sigma receptor gene and schizophrenia. Neumsci. Lett. 257,45-48 (1998).
   Google Scholar
• Ohmori O, Shinkai T, Suzuki T et al. Polymorphisms of the sigma(1) receptor gene in schizophrenia: An association study. Am.J. Med. Genet. 96,118-122 (2000).
   Google Scholar
• Song W, Nadeau P, Yuan M et al Proteolytic release and nuclear translocation of Notch-1 are induced by presenilin-1 and impaired by pathogenic presenilin-1 mutations. Proc. Natl Acad. Sci. USA 96, 6959–6963 (1999).
   Google Scholar
• Sestan N, Artavanis-Tsakonas S, Rakic P. Contact-dependent inhibition of cortical neurite growth mediated by notch signaling. Science 286,741–746 (1999).
   PubMed Web of Science ®Google Scholar
• Joutel A, Corpechot C, Ducros A eta]. Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia. Natum 383,707–710 (1996).
   Google Scholar
• Wei J, Hemmings GP. The NOTCH4 locus is associated with susceptibility to schizophrenia. Nat. Genet. 25,376-377 (2000).
   Google Scholar
• Ujike H, Takehisa Y, Takaki M eta]. NOTCH4 gene polymorphism and susceptibility to schizophrenia and schizoaffective disorder. Neurosci. Lett. 301, 41–44 (2001).
   Google Scholar
• Sklar P, Schwab SG, Williams NM etal Association analysis of NOTCH4 loci in schizophrenia using family and population-based controls. Nat. Genet. 28,126-128 (2001).
   Google Scholar
• McGinnis RE, Fox H, Yates P eta]. Failure to confirm NOTCH4 association with schizophrenia in a large population-based sample from Scotland. Nat. Genet. 28, 128–129 (2001).
   Google Scholar
• Hollister LE. Health aspects of cannabis. Pharmacol Rev. 38,1–20 (1986).
   PubMed Web of Science ®Google Scholar
• Andreasson S, Allebeck P, Engstrom A etal Cannabis and schizophrenia. A longitudinal study of Swedish conscripts. Lancet2, 1483–1486 (1987).
   Google Scholar
• Ujike H, Takaki M, Nakata K etal CNR1, central cannabinoid receptor gene, associated with susceptibility to hebephrenic schizophrenia. Mal Psychiatry 7,515–518 (2002).
   PubMed Web of Science ®Google Scholar
• •First genetic evidence for cannabinoid hypothesis of schizophrenia.
   Google Scholar
• Tsai SJ, Wang YC, Hong CJ. Association study of a cannabinoid receptor gene (CNR1) polymorphism and schizophrenia. Psychiatr Genet. 10,149-151 (2000).
   Google Scholar
• Di Marzo V, Melck D, Bisogno T et al Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action. Wends Neurosci 21,521–528 (1998).
   Google Scholar
• Dean B, Sundram S, Bradbury R etal Studies on [3T-11CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use. Neuroscience 103,9–15 (2001).
   PubMed Web of Science ®Google Scholar
• Hamajima N, Matsuda K, Sokoto S etal A novel gene family defined by human dihydropyrimidinase and three related proteins with differential tissue distribution. Gene 180,157–163 (1996).
   PubMedGoogle Scholar
• Koyama K, Sudo K, Nakamura Y. Isolation of 115 human chromosome 8-specific expressed-sequence tags by exon amplification. Genomics 26,245–253 (1995).
   Google Scholar
• Johnston-Wilson NL, Sims CD, Hofmann JP etal Disease-specific alterations in frontal cortex brain proteins in schizophrenia, bipolar disorder and major depressive disorder. The Stanley Neuropathology Consortium. Mal Psychiatry 5,142–149 (2000).
   PubMed Web of Science ®Google Scholar
• Nakata K, Ujike H, Sakai A eta]. The human dihydropyriminidase-related protein 2 gene on chromosome 8p21 is associated with paranoid-type schizophrenia. Biol. Psychiatry (In Press).
   Google Scholar
• •First evidence of DRP-2 gene as a negative risk factor for schizophrenia.
   Google Scholar
• Murphy KC. Schizophrenia and velo— cardio—facial syndrome. Lancet 359,426–430 (2002).
   PubMed Web of Science ®Google Scholar
• Karayiorgou M, Morris MA, Morrow B eta]. Schizophrenia susceptibility associated with interstitial deletions of chromosome 22q11. Proc. Natl Acad. Li. USA 92,7612–7616 (1995).
   Google Scholar
• Bassett AS, Chow EW. 22q11 deletion syndrome: a genetic subtype of schizophrenia. Biol. PTchiatry46, 882–891 (1999).
   Google Scholar
• •Good review of 22q11 DGS syndrome and schizophrenia.
   Google Scholar
• Ujike H, Takehisa Y, Takaki M et al. Del/ Ins polymorphism in DGCR6 gene in chromosome 22 and schizophrenia. Arn. Med. Genet. 96, 532 (2000).
   Google Scholar
• Liu H, Heath SC, Sobin C etal Genetic variation at the 22q11 PRODH2/DGCR6 locus presents an unusual pattern and increases susceptibility to schizophrenia. Proc. Nat/Acad. Li USA 99, 3717–3722 (2002).
   Google Scholar
• •First report of an association between PRODH2 gene and schizophrenia.
   Google Scholar
• Jacquet H, Raux G, Thibaut F eta]. PRODHmutations and hyperprolinemia in a subset of schizophrenic patients. Hum. Mal Genet. 11, 2243–2249 (2002).
   Google Scholar
• St Clair D, Blackwood D, Muir W eta]. Association within a family of a balanced autosomal translocation with major mental illness. Lancet 336, 13–16 (1990).
   Google Scholar
• Millar JK, Wilson-Annan JC, Anderson S etal Disruption of two novel genes by a translocation co-segregating with schizophrenia. Hum. Mal Genet. 9, 1415–1423 (2000).
   PubMed Web of Science ®Google Scholar
• Ekelund J, Hovatta I, Parker A et al Chromosome 1 loci in Finnish schizophrenia families. Hum. Mal Genet. 10, 1611–1617 (2001).
   Google Scholar
• •First positive linkage study for DISC-1 gene and schizophrenia.
   Google Scholar
• Straub RE, Jiang Y, MacLean CJ et al Genetic variation in the 6p22.3 gene DTNBP1, the human ortholog of the mouse dysbindin gene, is associated with schizophrenia. Arn. J. Hum. Genet. 71, 337–348 (2002).
   Google Scholar
• Stefansson H, Sigurdsson E, Steinthorsdottir V eta]. Neuregulin 1 and susceptibility to schizophrenia. Am. J. Hum. Genet. 71,877-892 (2002).
   Google Scholar
• •First report of neuregulin-1 and schizophrenia.
   Google Scholar